search
Back to results

iCanCope With Sickle Cell Pain

Primary Purpose

Sickle Cell Disease

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Pain self-management
Education
Sponsored by
Seattle Children's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sickle Cell Disease

Eligibility Criteria

12 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • aged between 12-18 years
  • diagnosed with any type of SCD
  • able to speak and read English
  • score at least 4 (indicating some days with pain interference over the past month) on the Sickle Cell Pain Burden Interview
  • willing and able to complete online measures

Exclusion Criteria:

  • significant cognitive limitations that would impair their ability to use and understand the iCanCope with SCD program, as per their healthcare provider or parent
  • have previously received more than 4 sessions of outpatient psychological therapy for pain management in the 6 months prior to the time of screening.

Sites / Locations

  • Connecticut Children's Medical Center
  • Emory University
  • Seattle Children's Hospital
  • The Hospital for Sick Children

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Education Control

Pain Self-Management Intervention

Arm Description

In addition to standard medical care, youth in the education control group will be provided with access to a self-guided education study website, which will contain static education about SCD (no self-management skills, goal-setting, or social support content) to access over 8-weeks.

In addition to standard medical SCD care, youth in the pain self-management intervention group will receive the iCanCope with SCD mobile intervention including goal-setting, peer social support, and pain self-management skills over a period of 8 weeks.

Outcomes

Primary Outcome Measures

Pain diary
App diary using an 11-point numerical rating scale for pain intensity and Child Activity Limitations Inventory 9-items to measure activity limitations for 7 days
Adaptive coping
Coping Strategies Questionnaire for Sickle Cell Disease

Secondary Outcome Measures

Treatment acceptability
Treatment Evaluation Inventory
Physical and emotional functioning
Patient-reported Outcomes Measurement Information System (PROMIS) Pediatric Profile: depressive symptoms, anxiety, mobility, pain interference, fatigue, peer relationships
Patient Global Impression of Change
Global rating for improvement in pain and functioning
Parent protectiveness
Adult Responses to Children's Symptoms
Health services utilization
Client Services Receipt Inventory adapted for sickle cell disease
Parent psychological distress
Symptom Checklist 90
Child physical and emotional functioning
Bath Adolescent Pain Questionnaire - Parent version assesses social functioning (score range: 0-36), physical functioning (0-36), depression (0-24), general anxiety (0-28), pain specific anxiety (0-28), family functioning (0-48) and development (0-44). A higher score indicates more impaired functioning for all subscales.
Unwanted treatment effects
Self report of adverse events during treatment. The number of participants with unwanted treatment effects will be reported.

Full Information

First Posted
June 23, 2017
Last Updated
December 30, 2022
Sponsor
Seattle Children's Hospital
Collaborators
The Hospital for Sick Children, Emory University, Connecticut Children's Medical Center, University of Mississippi Medical Center, University of Florida, Boston Medical Center, Northwestern University
search

1. Study Identification

Unique Protocol Identification Number
NCT03201874
Brief Title
iCanCope With Sickle Cell Pain
Official Title
iCanCope With Sickle Cell Disease: A Mobile Pain Management Intervention for Adolescents
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Completed
Study Start Date
January 1, 2018 (Actual)
Primary Completion Date
August 31, 2022 (Actual)
Study Completion Date
August 31, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seattle Children's Hospital
Collaborators
The Hospital for Sick Children, Emory University, Connecticut Children's Medical Center, University of Mississippi Medical Center, University of Florida, Boston Medical Center, Northwestern University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The project will test a tailored web and smartphone-based application (iCanCope with SCD) to improve pain self-management and functioning in youth (aged 12-18) with sickle cell disease. The program will include goal setting, peer-based social support, and pain self-management training. The investigators will determine initial program effectiveness through a pilot three-site randomized controlled trial in 160 youth randomized to treatment compared to attention control.
Detailed Description
Cognitive-behavioral therapies (CBT) that promote pain self-management can lead to symptom reduction, improved quality of life, and decreased healthcare use. However, most people with SCD do not receive CBT-based treatment due to barriers such as poor accessibility, limited availability of professionals, and high costs. First, the investigators plan to apply a user-centered design approach to develop and refine the iCanCope with SCD program. Second, program feasibility and initial program effectiveness will be determined through a pilot three-site randomized controlled trial. The investigators will determine study accrual and dropout rates as well as levels of patient acceptability and engagement. Preliminary effectiveness will be determined in youth receiving treatment compared to attention control on a range of physical, behavioral, and psychosocial outcomes assessed at post-treatment and 6-month follow-up. Third, moderators and mediators of treatment effect will be tested by examining whether differences in self-efficacy and patient activation predict changes in pain and functioning. These results will enable a future full-scale randomized controlled trial.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sickle Cell Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
137 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Education Control
Arm Type
Active Comparator
Arm Description
In addition to standard medical care, youth in the education control group will be provided with access to a self-guided education study website, which will contain static education about SCD (no self-management skills, goal-setting, or social support content) to access over 8-weeks.
Arm Title
Pain Self-Management Intervention
Arm Type
Experimental
Arm Description
In addition to standard medical SCD care, youth in the pain self-management intervention group will receive the iCanCope with SCD mobile intervention including goal-setting, peer social support, and pain self-management skills over a period of 8 weeks.
Intervention Type
Behavioral
Intervention Name(s)
Pain self-management
Intervention Description
The program is designed to enhance self-efficacy. The app will guide youth in setting structured and personalized goals aimed at improving their pain and functioning. The pain self-management skills will include personalized CBT-based coping skills including deep breathing, relaxation, and cognitive skills (e.g., staying positive). The app will provide in-the-moment access to pain coping strategies to promote positive changes in mood, behavior, and pain.
Intervention Type
Behavioral
Intervention Name(s)
Education
Intervention Description
Education about sickle cell disease to increase disease knowledge
Primary Outcome Measure Information:
Title
Pain diary
Description
App diary using an 11-point numerical rating scale for pain intensity and Child Activity Limitations Inventory 9-items to measure activity limitations for 7 days
Time Frame
Change from baseline to 12 weeks and 26 weeks
Title
Adaptive coping
Description
Coping Strategies Questionnaire for Sickle Cell Disease
Time Frame
Change from baseline to 12 weeks and 26 weeks
Secondary Outcome Measure Information:
Title
Treatment acceptability
Description
Treatment Evaluation Inventory
Time Frame
2 months after starting treatment
Title
Physical and emotional functioning
Description
Patient-reported Outcomes Measurement Information System (PROMIS) Pediatric Profile: depressive symptoms, anxiety, mobility, pain interference, fatigue, peer relationships
Time Frame
Change from baseline to 12 weeks and 26 weeks
Title
Patient Global Impression of Change
Description
Global rating for improvement in pain and functioning
Time Frame
12 weeks and 26 weeks
Title
Parent protectiveness
Description
Adult Responses to Children's Symptoms
Time Frame
Change from baseline to 12 weeks and 26 weeks
Title
Health services utilization
Description
Client Services Receipt Inventory adapted for sickle cell disease
Time Frame
Change from baseline to 26 weeks
Title
Parent psychological distress
Description
Symptom Checklist 90
Time Frame
Change from baseline to 12 weeks and 26 weeks
Title
Child physical and emotional functioning
Description
Bath Adolescent Pain Questionnaire - Parent version assesses social functioning (score range: 0-36), physical functioning (0-36), depression (0-24), general anxiety (0-28), pain specific anxiety (0-28), family functioning (0-48) and development (0-44). A higher score indicates more impaired functioning for all subscales.
Time Frame
Change from baseline to 12 weeks and 26 weeks
Title
Unwanted treatment effects
Description
Self report of adverse events during treatment. The number of participants with unwanted treatment effects will be reported.
Time Frame
12 weeks and 26 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: aged between 12-18 years diagnosed with any type of SCD able to speak and read English score at least 4 (indicating some days with pain interference over the past month) on the Sickle Cell Pain Burden Interview willing and able to complete online measures Exclusion Criteria: significant cognitive limitations that would impair their ability to use and understand the iCanCope with SCD program, as per their healthcare provider or parent have previously received more than 4 sessions of outpatient psychological therapy for pain management in the 6 months prior to the time of screening.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tonya M Palermo, PhD
Organizational Affiliation
Seattle Children's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Connecticut Children's Medical Center
City
Hartford
State/Province
Connecticut
ZIP/Postal Code
06106
Country
United States
Facility Name
Emory University
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Name
Seattle Children's Hospital
City
Seattle
State/Province
Washington
ZIP/Postal Code
98105
Country
United States
Facility Name
The Hospital for Sick Children
City
Toronto
State/Province
Ontario
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
36040789
Citation
Lalloo C, Nishat F, Zempsky W, Bakshi N, Badawy S, Ko YJ, Dampier C, Stinson J, Palermo TM. Characterizing User Engagement With a Digital Intervention for Pain Self-management Among Youth With Sickle Cell Disease and Their Caregivers: Subanalysis of a Randomized Controlled Trial. J Med Internet Res. 2022 Aug 30;24(8):e40096. doi: 10.2196/40096.
Results Reference
derived

Learn more about this trial

iCanCope With Sickle Cell Pain

We'll reach out to this number within 24 hrs